SSDI for Cancer in Michigan

Reviewed by Kelly M. Neumann, a Michigan Social Security Disability Lawyer and Principal Attorney at Neumann Law Group. Last updated August 26, 2026.

Cancer claims divide into two groups that need entirely different files, and the first thing our Social Security Disability attorneys establish is which one a Michigan client is in. Some claims are decided almost entirely by a pathology report, and the work is documentary. Others involve a cancer that responded to treatment while the treatment itself left damage that is still measurable years later, and those claims are won or lost on functional evidence that oncology records were never designed to capture.

How Do the 13.00 Cancer Listings Work?

The 13.00 listings cover all cancers other than certain HIV-associated malignancies, which are routed to the immune system listings at 14.11. Within 13.00 the organizing principle is anatomical rather than diagnostic. The regulation is explicit that the agency applies the criteria in a specific listing to a cancer originating from that specific site, so soft tissue cancers of the head and neck are evaluated under 13.02, lymphoma under 13.05, leukemia under 13.06, multiple myeloma under 13.07, breast cancer under 13.10, and lung cancer under 13.14, among roughly two dozen site-specific listings. Where the primary site cannot be identified at all, the agency uses documentation of the sites of metastasis and evaluates the claim under 13.27. The four considerations the regulation names run through all of them: the origin of the cancer, the extent of involvement, the duration and frequency of and response to anticancer therapy, and the effects of any post-therapeutic residuals.

What Makes One Cancer Claim Stronger Than Another?

Stage and resectability do most of the work at step three. Many site-specific listings are written around disease that is inoperable, unresectable, recurrent after an initial course of treatment, or that has spread beyond the regional lymph nodes, which means the same diagnosis produces opposite outcomes depending on what the imaging and the pathology actually showed. A claimant whose tumor was resected with clear margins and who completed adjuvant therapy will usually not meet a listing on the disease itself, and their claim, if they have one, rests on what treatment left behind. A claimant with distant metastases frequently satisfies the criteria on the documentation alone, and the regulation acknowledges this by providing that longitudinal evidence is generally unnecessary in that situation.

Do Treatment Side Effects Support a Michigan SSDI Claim?

They are often the whole claim, and they are the part of the record most likely to be underdocumented. The regulation directs the agency to weigh the duration, frequency, and response to anticancer therapy and the effects of post-therapeutic residuals, which brings the consequences of treatment squarely within the analysis rather than leaving them as background. Peripheral neuropathy from platinum-based or taxane agents can persist for years after the last infusion and is evaluated under Listing 11.14 in the neurological body system. Cardiac damage from anthracyclines or from chest radiation is evaluated under the 4.00 listings. Persistent cognitive change and the fatigue that follows extended treatment are assessed for their effect on concentration, persistence, and pace. Where none of these meets a listing on its own, they combine into a residual functional capacity assessment under 20 C.F.R. § 404.1545, which requires the agency to weigh every medically determinable impairment, including those it does not find severe.

What Evidence Does a Cancer Disability Claim Require?

The regulation is unusually specific about documentation here, and following it closely removes most of the friction from these claims. The agency needs medical evidence specifying the type, extent, and site of the primary, recurrent, or metastatic lesion. For any operative procedure, including a biopsy or a needle aspiration, it generally needs both the operative note and the pathology report, and claimants routinely submit one without the other because the pathology report is what their oncologist discussed with them. Where neither document can be obtained, a hospitalization summary or other medical report containing the surgical and pathological findings will be accepted. Imaging reports establish the extent of involvement and any distant spread, and the staging documentation that accompanies them frequently answers the listing question directly.

For a claim resting on treatment effects the useful records are different and are usually thinner. Chemotherapy and radiation administration records establish the agents used, the number of cycles, and any dose reductions or discontinuations, which evidence both the intensity of treatment and the body’s failure to tolerate it. Electrodiagnostic testing documents persistent neuropathy in objective terms. Echocardiography documents cardiac residuals. Records of hospitalization for neutropenia, infection, or dehydration during treatment show a course that was not routine. A treating oncologist’s statement addressing sustained concentration, expected absences, and tolerance for a full workday supplies what none of the clinical records will state on their own.

How Neumann Law Group Prepares a Michigan Cancer Claim

We begin with the pathology and staging documents rather than the narrative summaries, since those two records usually determine whether a listing-level claim exists and there is little point building elsewhere until that is settled. Where the disease itself satisfies a site-specific listing, our attorneys keep the file tight and documentary and press for a decision rather than developing evidence the claim does not need. Where the cancer responded and the claim rests on residuals, we rebuild the file around the body systems the treatment damaged, which usually means obtaining neurology and cardiology records the oncology chart only references. We ask the treating oncologist to address absences and sustained pace explicitly, because a vocational expert will be asked what employers tolerate, and a documented monthly absence estimate is the fact that answers it.

What to Do Now With a Michigan Cancer Disability Claim

Request the operative note and the pathology report for every procedure, including biopsies, and confirm you have both rather than one. Obtain the staging documentation and the imaging reports that established the extent of the disease, not the summaries quoting them. Ask your oncology team for the complete treatment administration records showing every agent, cycle, dose reduction, and delay. If treatment ended and symptoms did not, ask which physician should evaluate the residual problem, since neuropathy and cardiac damage are assessed under different body systems than the cancer. Keep a dated record of the days treatment or its aftereffects prevented ordinary activity. Where the primary site was never identified, make sure the file documents each site of metastasis, because that is the evidence Listing 13.27 is built on.

Frequently Asked Questions About Cancer SSDI Claims in Michigan

Does a Cancer Diagnosis Automatically Qualify for SSDI?

No. The 13.00 listings apply criteria specific to the site the cancer originated from, and many of them turn on whether the disease is inoperable, unresectable, recurrent after treatment, or has spread beyond regional nodes. A cancer caught early and treated successfully generally will not meet a listing, while the same diagnosis found at an advanced stage may meet one on the pathology alone.

Which Listing Applies to My Cancer?

The one for the site where the cancer originated. The regulation states that the agency applies the criteria in a specific listing to a cancer originating from that specific site, so breast cancer is evaluated under 13.10 and lung cancer under 13.14 regardless of where the disease has since spread. Where the primary site cannot be identified, the agency uses evidence of the sites of metastasis and evaluates the claim under 13.27.

What Records Does SSA Need for a Cancer Claim?

Medical evidence specifying the type, extent, and site of the primary, recurrent, or metastatic lesion. For any operative procedure, including a biopsy or needle aspiration, the agency generally needs both the operative note and the pathology report. Where those documents cannot be obtained it will accept a hospitalization summary or other medical reports containing the surgical and pathological findings.

Can Treatment Side Effects Support a Disability Claim?

Yes, and they frequently do. The regulation directs the agency to consider the duration, frequency, and response to anticancer therapy and the effects of post-therapeutic residuals. Neuropathy from platinum or taxane agents, cardiac damage from certain regimens, cognitive change, and persistent fatigue are evaluated for their functional consequences even after the disease itself responds to treatment.

How Long Must a Cancer Claim Last to Qualify?

The impairment must have lasted or be expected to last at least 12 months or to result in death, the same duration requirement that applies to every disability claim. That requirement is rarely the obstacle in an advanced cancer case, and for cancer with distant metastases the agency generally does not need longitudinal evidence before finding the criteria satisfied.

Related Practice Areas

Chemotherapy-induced neuropathy is evaluated in the body system covered on the firm’s neurological conditions page. Claimants whose treatment damaged the heart will find those criteria set out on the heart disease page. Depression and cognitive change following a cancer course are assessed under the standard described on the mental health conditions page.